NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category (Ascending) | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|
68071-1987-03 | 68071-1987 | Ondansetron | Ondansetron | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Feb. 23, 2017 | In Use | |
68071-1987-04 | 68071-1987 | Ondansetron | Ondansetron | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Feb. 23, 2017 | In Use | |
68071-1987-06 | 68071-1987 | Ondansetron | Ondansetron | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Feb. 23, 2017 | In Use | |
68071-2147-01 | 68071-2147 | Ondansetron Hydrochloride | Ondansetron Hydrochloride | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Jan. 25, 2017 | In Use | |
68071-3028-02 | 68071-3028 | Ondansetron | Ondansetron | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | March 14, 2017 | In Use | |
68071-3028-04 | 68071-3028 | Ondansetron | Ondansetron | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | March 14, 2017 | In Use | |
68071-3195-02 | 68071-3195 | Ondansetron | Ondansetron | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | March 29, 2017 | Dec. 31, 2019 | No Longer Used |
68071-3195-04 | 68071-3195 | Ondansetron | Ondansetron | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | March 29, 2017 | Dec. 31, 2019 | No Longer Used |
68071-3275-05 | 68071-3275 | Ondansetron Hydrochloride | Ondansetron | 4.0 mg/5mL | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | June 12, 2017 | March 31, 2020 | No Longer Used |
68151-1668-08 | 68151-1668 | Ondansetron Hydrochloride | Ondansetron Hydrochloride | 4.0 mg/5mL | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Dec. 26, 2006 | In Use | |
68151-2959-06 | 68151-2959 | Anagrelide Hydrochloride | Anagrelide Hydrochloride | 0.5 mg/1 | Ancillary Therapy | Platelet-Reducing Agent | PDE-3 Inhibitor | Oral | April 18, 2005 | In Use | |
68220-0055-10 | 68220-0055 | Oxymetholone | Anadrol-50 | 50.0 mg/1 | Ancillary Therapy | Anabolic Steroid | Androgen | Oral | June 1, 1972 | Feb. 28, 2021 | In Use |
68258-7068-01 | 68258-7068 | Ondansetron | Ondansetron | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Nov. 8, 2011 | In Use | |
68258-7068-06 | 68258-7068 | Ondansetron | Ondansetron | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | June 27, 2007 | In Use | |
68094-0763-59 | 68094-0763 | Ondansetron Hydrochloride | Ondansetron Hydrochloride | 4.0 mg/5mL | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Feb. 27, 2015 | In Use | |
68094-0763-62 | 68094-0763 | Ondansetron Hydrochloride | Ondansetron Hydrochloride | 4.0 mg/5mL | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Feb. 27, 2015 | In Use | |
68788-9329-01 | 68788-9329 | Ondansetron | Ondansetron | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | March 31, 2015 | Nov. 8, 2019 | No Longer Used |
68788-9329-03 | 68788-9329 | Ondansetron | Ondansetron | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | March 31, 2015 | Nov. 8, 2019 | No Longer Used |
68788-9329-05 | 68788-9329 | Ondansetron | Ondansetron | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | March 31, 2015 | Nov. 8, 2019 | No Longer Used |
68788-9770-01 | 68788-9770 | Ondansetron | Ondansetron | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | July 27, 2012 | Nov. 8, 2019 | No Longer Used |
68788-9770-03 | 68788-9770 | Ondansetron | Ondansetron | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | July 27, 2012 | Nov. 8, 2019 | No Longer Used |
68788-9770-05 | 68788-9770 | Ondansetron | Ondansetron | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | July 27, 2012 | Nov. 8, 2019 | No Longer Used |
68788-9892-01 | 68788-9892 | Ondansetron Hydrochloride | Ondansetron Hydrochloride | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Feb. 14, 2012 | Nov. 8, 2019 | No Longer Used |
68788-9892-03 | 68788-9892 | Ondansetron Hydrochloride | Ondansetron Hydrochloride | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Feb. 14, 2012 | Nov. 8, 2019 | No Longer Used |
68788-9893-01 | 68788-9893 | Ondansetron Hydrochloride | Ondansetron Hydrochloride | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Feb. 14, 2012 | Nov. 8, 2019 | No Longer Used |
68788-9893-03 | 68788-9893 | Ondansetron Hydrochloride | Ondansetron Hydrochloride | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Feb. 14, 2012 | Nov. 8, 2019 | No Longer Used |
69189-7732-01 | 69189-7732 | Ondansetron | Ondansetron | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | March 4, 2016 | May 24, 2017 | No Longer Used |
70518-0235-00 | 70518-0235 | Ondansetron | Ondansetron | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Feb. 17, 2017 | Nov. 9, 2018 | In Use |
70518-0291-00 | 70518-0291 | Ondansetron | Ondansetron | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | March 8, 2017 | March 14, 2019 | In Use |
70518-0291-01 | 70518-0291 | Ondansetron | Ondansetron | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | March 16, 2017 | May 17, 2018 | In Use |
70518-1394-00 | 70518-1394 | Ondansetron Hydrochloride | Ondansetron Hydrochloride | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Aug. 29, 2018 | In Use | |
70518-1422-00 | 70518-1422 | Ondansetron Hydrochloride | Ondansetron | 2.0 mg/mL | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Intramuscular, Intravenous | Sept. 18, 2018 | Oct. 11, 2019 | In Use |
70518-2895-00 | 70518-2895 | Ondansetron | Ondansetron | 2.0 mg/mL | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Intramuscular, Intravenous | Sept. 25, 2020 | In Use | |
70934-0206-83 | 70934-0206 | Ondansetron | Ondansetron | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Feb. 6, 2020 | In Use | |
70934-0206-87 | 70934-0206 | Ondansetron | Ondansetron | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | July 19, 2019 | In Use | |
70934-0206-88 | 70934-0206 | Ondansetron | Ondansetron | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Feb. 15, 2019 | In Use | |
70934-0206-95 | 70934-0206 | Ondansetron | Ondansetron | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Feb. 4, 2019 | In Use | |
70934-0206-99 | 70934-0206 | Ondansetron | Ondansetron | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Feb. 12, 2019 | In Use | |
70934-0448-83 | 70934-0448 | Ondansetron | Ondansetron | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | April 8, 2020 | In Use | |
70934-0448-95 | 70934-0448 | Ondansetron | Ondansetron | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Sept. 26, 2020 | In Use | |
75921-0459-10 | 75921-0459 | Ondansetron | Ondansetron | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | June 25, 2007 | In Use | |
89141-0448-01 | 89141-0448 | Ondansetron | Zuplenz | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | July 2, 2010 | Feb. 23, 2021 | In Use |
89141-0448-30 | 89141-0448 | Ondansetron | Zuplenz | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Dec. 31, 2016 | Feb. 23, 2021 | In Use |
69097-0927-35 | 69097-0927 | Palonosetron hydrochloride | Palonosetron hydrochloride | 0.25 mg/5mL | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Intravenous | March 23, 2018 | In Use | |
69189-5241-01 | 69189-5241 | Anagrelide Hydrochloride | Anagrelide Hydrochloride | 0.5 mg/1 | Ancillary Therapy | Platelet-Reducing Agent | PDE-3 Inhibitor | Oral | July 15, 2015 | May 24, 2017 | No Longer Used |
69656-0101-02 | 69656-0101 | Rolapitant | Varubi | 90.0 mg/1 | Ancillary Therapy | Antiemetic | Substance P/Neurokinin 1 | Oral | Oct. 7, 2015 | Oct. 31, 2021 | No Longer Used |
70934-0384-06 | 70934-0384 | Metoclopramide | Metoclopramide | 10.0 mg/1 | Ancillary Therapy | Antiemetic | Dopamine-2 Receptor Antagonist | Oral | June 3, 2019 | In Use | |
70934-0548-30 | 70934-0548 | Metoclopramide | Metoclopramide | 10.0 mg/1 | Ancillary Therapy | Antiemetic | Dopamine-2 Receptor Antagonist | Oral | Feb. 26, 2020 | In Use | |
76045-0101-20 | 76045-0101 | Metoclopramide Hydrochloride | Metoclopramide | 10.0 mg/2mL | Ancillary Therapy | Antiemetic | Dopamine-2 Receptor Antagonist | Intramuscular, Intravenous | May 3, 2013 | In Use | |
13668-0453-01 | 13668-0453 | Anagrelide | Anagrelide | 0.5 mg/1, 0.5 mg/1 | Ancillary Therapy | Platelet-Reducing Agent | PDE-3 Inhibitor | Oral | June 30, 2017 | In Use |
Found 10,000 results in 5 milliseconds — Export these results